What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
PEGylated Mechano Growth Factor
Vialdyne buyer fit
This Vialdyne page is intentionally positioned for compounding-pharmacy, clinic, and regulated procurement teams evaluating PEG MGF. It is not the broad research monograph for this SKU; the page emphasizes buyer qualification, release testing, documentation depth, and whether the active fits the destination-market workflow before pricing.
Overview
PEG-MGF is a polyethylene-glycol-conjugated derivative of MGF (Mechano Growth Factor, the IGF-1 Ec splice-variant peptide). The conjugation is engineered to push plasma stability well beyond the minutes-scale half-life of unmodified native MGF. The conjugation playbook mirrors what clinical PEG-protein assets like PEG-IFN and PEG-G-CSF have used for decades, attaching a polyethylene glycol polymer to one or more reactive groups on the peptide enlarges hydrodynamic radius, slows renal clearance, and shields the peptide from proteolytic attack. The cross-supplier comparison problem is that the PEG architecture itself varies materially across vendors: PEG MWs range from 5 kDa to 40 kDa, and attachment chemistry can be either site-specific (single-residue) or random (multi-site), with downstream PK consequences across both axes. For research-lab buyers, Vialdyne releases PEG-MGF as a lyophilised conjugate against a ≥99.0% main-peak HPLC specification. Because PEG MW and attachment site jointly govern the conjugate's PK profile, every released batch COA explicitly documents three values: PEG polymer mass, attachment chemistry (site-specific vs random), and PEG-to-peptide ratio. Cross-supplier qualification has to normalise across all three rather than comparing on peptide content alone, two materials sharing the catalogue label 'PEG-MGF' from different sources can differ by 5-10x in functional half-life depending on the PEG architecture choices. The COA structure is built to drop directly into a sponsor's QA file when supplier equivalence has to be defended in writing.
Applications & buyer fit
Repair peptides, BPC-157, TB-500, and related sequences, typically ship to research labs studying tissue-repair, gastrointestinal, or tendon-ligament models, and to compounding pharmacies that have validated the active material into their workflow. The synthesis itself is reliable, but analytical confirmation is where suppliers differ, buyers qualifying a new source should request sequence verification by tandem MS on the first batch and compare against the labelled sequence directly.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Buyers qualifying a new source typically request tandem-MS sequence verification on the first lot, compared against the labelled sequence.
Primary buyer fit: academic and contract research laboratories.
Specifications
Certificate of Analysis
Published released-batch COAs for PEG MGF, every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
Browse all published COAsRegulatory note
Supplier-to-supplier, this PEG conjugate varies in its architecture. Per batch COA, confirm the PEG molecular weight, the site of attachment, and the PEG-to-peptide ratio. Do not assume pharmacokinetic comparability from one supplier source to another.
Selected literature
Frequently asked questions
Because the PEG component is not a passive shield, it actively shapes PK. PEG polymer MW drives both hydrodynamic radius (which sets the renal-clearance threshold) and the overall conjugate molecular weight, both of which determine in vivo half-life. Attachment chemistry (site-specific vs random) drives product consistency, random conjugation produces an isomer mixture, and it also influences residual MGF biological activity because some attachment sites preserve activity better than others. The practical consequence: two PEG-MGF preparations from different suppliers can carry the same nominal label and differ by 5-10x in functional half-life. Any cross-supplier comparison has to be done against PEG MW, attachment site, and PEG-to-peptide ratio rather than against the label alone.
Two distinct use cases. For in vivo workflows, PEG-MGF is essentially required: native MGF's minute-scale plasma half-life would force impractical dosing frequency, while the PEGylated form extends functional half-life by 10-100x depending on PEG architecture, supporting once-daily or less-frequent dosing protocols. For cell-culture and biochemical-assay work, unmodified MGF is the right choice, the dose is added directly to a defined system, and stability across hours rather than days is sufficient. Published cell-culture studies overwhelmingly use unmodified MGF; published in vivo studies are split between PEG-MGF and other long-acting analogues.
Related peptides
